Pregabalin
| Evidence Level: L4 | Predicted Indications: 6 |
Table of Contents
Pregabalin: From Neuropathic Pain to Tendinitis
One-Sentence Summary
Pregabalin is an α2δ calcium-channel modulator whose established literature base relates to central and peripheral neuropathic pain pathways, though formal original-indication and mechanism-of-action data are missing from this evidence pack. The TxGNN model predicts it may be effective for Tendinitis, but this is currently supported by 0 clinical trials and only 6 publications, most of which are indirect (postoperative pain adjuvant use, case reports, or preclinical work unrelated to pregabalin itself).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in the current evidence pack (regulatory and MOA data are flagged as gaps — see DG001/DG002) |
| Predicted New Indication | Tendinitis |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for pregabalin is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on the information that is available, pregabalin’s literature footprint centres on modulation of central and peripheral neuropathic pain pathways — this is the mechanistic frame used within the evidence pack itself when assessing the tendinitis prediction.
Tendinitis, however, is fundamentally a mechanical and inflammatory soft-tissue injury rather than a neuropathic pain condition. The evidence pack’s own rationale for this candidate explicitly notes that the mechanistic link is weak and indirect: available literature largely concerns pregabalin’s use as a perioperative opioid-sparing analgesic adjunct after tendon-adjacent surgery (e.g. rotator cuff repair), not as a treatment directed at tendon inflammation or repair itself. No studies in this pack test pregabalin as a primary therapy for tendinitis.
Given this, the high TxGNN similarity score should be interpreted as a knowledge-graph structural signal rather than a validated pharmacological rationale — it identifies a candidate worth flagging, not one with an established biological case.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34052386 | 2022 | RCT | Arthroscopy | Randomised trial comparing perioperative oral pregabalin with interscalene brachial plexus block after arthroscopic rotator cuff repair; pregabalin produced comparable postoperative pain scores to nerve block, but this evaluates pain control, not tendinitis treatment. |
| 32839073 | 2021 | RCT | J Orthop Sci | Retrospective cohort study of pregabalin’s analgesic and opioid-sparing effect after arthroscopic rotator cuff repair; adjunctive perioperative use, not a tendinitis-specific therapeutic endpoint. |
| 40818536 | 2025 | Review | Arthroscopy | Editorial commentary on piriformis syndrome as a nerve/tendon compression disorder requiring precise diagnosis; discusses surgical release, does not evaluate pregabalin pharmacotherapy. |
| 41017607 | 2025 | Case Report | Praxis | Case report of fluoroquinolone (ciprofloxacin)-associated tendinopathy and disability; illustrates tendon injury pathophysiology but does not assess pregabalin as an intervention. |
| 37051935 | 2023 | Case Report | Pain Practice | Case report of posterior femoral cutaneous nerve impingement caused by hamstring tendonitis in a marathon runner; describes nerve-tendon interaction, no pregabalin treatment data. |
| 39703364 | 2024 | Preclinical | Adv Pharmacol Pharm Sci | Rat model study of Cissus quadrangularis extract (not pregabalin) attenuating vincristine-induced peripheral neuropathy; tangentially related via antinociceptive mechanism research only. |
UK Market Information
Pregabalin is currently recorded as not marketed in this evidence pack, with 0 marketing authorisations on file. No licence, product, or approved-indication data is available for review at this time.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Conclusion and Next Steps
Decision: Hold
Rationale: No clinical trials support pregabalin for tendinitis, and the available literature is indirect — largely perioperative opioid-sparing studies or unrelated case reports — with the evidence pack’s own analysis rating the mechanistic link as weak. This does not meet the bar for further evaluation at this time.
To proceed, the following is needed:
- TFDA/MHRA product label data (warnings, contraindications) — currently a Blocking gap (DG001)
- Verified mechanism-of-action data — currently a High-severity gap (DG002)
- Disease-specific preclinical or clinical evidence directly testing pregabalin in tendinitis (rather than adjunctive perioperative pain control)
- Formal documentation of pregabalin’s original licensed indication(s) for baseline comparison
Note: This evidence pack also contains other predicted indications for pregabalin with substantially stronger evidence — notably migraine disorder (Evidence Level L2, decision stage S2, “Research Question”), which is supported by completed RCTs, a Cochrane systematic review, and mechanistic/imaging studies on cortical spreading depression. If prioritising a candidate from this pack, migraine disorder is a considerably stronger starting point than tendinitis.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.